Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
GLP-1 (glucagon-like peptide-1) receptor agonists are a breakthrough class of FDA-approved weight loss and diabetes medications. They include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda). While these medications can have significant list prices, many patients pay far less through insurance coverage, manufacturer copay assistance, and savings card programs.
Clinical evidence shows 15-22% average body weight reduction over approximately 72 weeks — making GLP-1 therapy one of the most cost-effective long-term investments in your health when weighing medical outcomes against medication costs and the expense of obesity-related conditions.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 6, 2026
Telehealth consultations eliminate the cost of office visits, specialist referrals, and lab fees often required with in-person care. Everything happens online — affordably and efficiently.
All FDA-approved GLP-1 medications — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda) — are available with manufacturer savings programs that can reduce costs significantly.
Our network of board-certified physicians and support staff can help navigate insurance coverage, prior authorization processes, and identify the best savings programs to minimize your out-of-pocket cost.
Three landmark randomized controlled trials in the New England Journal of Medicine form the evidence base for FDA-approved GLP-1 weight management medications:
Telehealth prescribing of GLP-1 medications is fully legal in all 50 states when conducted by a properly licensed physician through a HIPAA-compliant platform. GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are not DEA-scheduled controlled substances — no in-person visit is required by federal or state telehealth law.
Adult obesity rates (CDC Behavioral Risk Factor Surveillance System, 2023) vary significantly across the United States. States with higher obesity prevalence experience the greatest demand for accessible GLP-1 telehealth prescriptions:
Source: CDC Behavioral Risk Factor Surveillance System (BRFSS) 2023. Adult obesity defined as BMI ≥ 30.0.
Select your state to explore insurance-friendly GLP-1 telehealth options and available savings programs in your area.
Patients in the largest US cities are accessing GLP-1 prescriptions online with insurance support and manufacturer savings. Find your city below.
Our process is designed to make GLP-1 medications as financially accessible as possible — not just medically accessible.
Start with a no-cost eligibility assessment. Provide your health information so our physicians can determine whether you qualify for GLP-1 therapy and which medications may be covered by your insurance plan.
A board-certified physician conducts your telehealth consultation and works with you to identify the most cost-effective GLP-1 option. We help you understand your insurance benefits and available manufacturer savings programs before prescribing.
Your GLP-1 medication ships directly to your door from a licensed US pharmacy. Home delivery eliminates the markup of retail pharmacy visits. Most patients receive their medication within 3-5 business days.
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
List prices for GLP-1 medications vary, but many patients pay significantly less through insurance coverage or manufacturer savings programs. Wegovy and Ozempic manufacturer programs can reduce costs to as little as $0-25 per month for eligible patients. Our physicians can help identify the most affordable option for your situation.
Many private insurance plans and some Medicare/Medicaid plans cover GLP-1 medications when prescribed for FDA-approved indications. Coverage depends on your specific plan, the medication prescribed, and documented medical need. Our team can help with prior authorization support.
Yes. Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro, Zepbound) both offer robust savings card programs. Eligible commercially insured patients may pay as little as $0 per month. Uninsured patients can explore patient assistance programs. Ask about savings options during your consultation.
Typically, yes. Telehealth eliminates office visit copays, specialist referral costs, and the time and transportation costs of in-person visits. Many patients find the total cost of telehealth GLP-1 care — including consultations and medication — to be comparable to or lower than traditional pathways.
If cost is a barrier, discuss this openly with your physician during consultation. Options include manufacturer patient assistance programs, coupon services, alternative GLP-1 agents with different cost profiles, and insurance appeal support. No one should be denied access to effective care due to cost alone.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
